Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mark Aleynick"'
Autor:
Judit Svensson-Arvelund, Sara Cuadrado-Castano, Gvantsa Pantsulaia, Kristy Kim, Mark Aleynick, Linda Hammerich, Ranjan Upadhyay, Michael Yellin, Henry Marsh, Daniel Oreper, Suchit Jhunjhunwala, Christine Moussion, Miriam Merad, Brian D. Brown, Adolfo García-Sastre, Joshua D. Brody
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Strategies to advance T cell based immune therapies are mostly focusing on the improvement of CD8 T cell effector functions, such as cytotoxicity or recruitment to the tumor. Here authors show that by combining in situ vaccination with oncolytic Newc
Externí odkaz:
https://doaj.org/article/d4dc7bf6f3c1411dac7c7248c9250073
Autor:
Michael Yellin, Miriam Merad, Henry Marsh, Ranjan Upadhyay, Judit Svensson-Arvelund, Daniel Oreper, Mark Aleynick, Gvantsa Pantsulaia, Kristy Kim, Samuel A Rose, Suchit Jhunjhunwala, Christine Carine Moussion, Brian D Brown, Joshua D Brody
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Cancer immunotherapies are generally effective in patients whose tumors contain a priori primed T-cells reactive to tumor antigens (TA). One approach to prime TA-reactive T-cells is to administer immunostimulatory molecules, cells, or path
Externí odkaz:
https://doaj.org/article/af511e4b189e4272917485ed9ec6c48a
Autor:
Joshua D. Brody, Miriam Merad, Brian D. Brown, Judit Svensson-Arvelund, Ranjan Upadhyay, Linda Hammerich, Mark Aleynick, Thomas U. Marron, Keino Hutchinson, Netonia Marshall
Transfer does not induce homeostatic inhibition on CD4+ T-cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091be4c1b38882232d975b4dd6fb3bad
https://doi.org/10.1158/2159-8290.22536995
https://doi.org/10.1158/2159-8290.22536995
Autor:
Joshua D. Brody, Miriam Merad, Brian D. Brown, Judit Svensson-Arvelund, Ranjan Upadhyay, Linda Hammerich, Mark Aleynick, Thomas U. Marron, Keino Hutchinson, Netonia Marshall
T-cell transfer into lymphodepleted recipients induces homeostatic activation and potentiates antitumor efficacy. In contrast to canonical T-cell receptor–induced activation, homeostatic activation yields a distinct phenotype and memory state whose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a6e73cf6497fd1859089df5ee1e3189
https://doi.org/10.1158/2159-8290.c.6548294.v1
https://doi.org/10.1158/2159-8290.c.6548294.v1
Autor:
Judit Svensson-Arvelund, Mark Aleynick, Aurélien Marabelle, Joshua Brody, Christopher R. Flowers
Publikováno v:
Clinical Cancer Research. 25:6283-6294
Immunotherapies such as checkpoint blockade have achieved durable benefits for patients with advanced stage cancer and have changed treatment paradigms. However, these therapies rely on a patient's own a priori primed tumor-specific T cells, limiting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d8b94e9fdbb55baafa235de3ab7ce5d
https://doi.org/10.1158/1078-0432.ccr-18-1800
https://doi.org/10.1158/1078-0432.ccr-18-1800
Autor:
Ephraim Kenigsberg, Joan Shang, Jovani Catalan, Tamar Plitt, Dan Fu Ruan, Katherine E. Lindblad, Jamie Redes, Francesca Cossarini, Zeynep H. Gümüş, Maria Casanova-Acebes, Julio A. Aguirre-Ghiso, Nina Bhardwaj, Robert M. Samstein, Venu Pothula, Uri Laserson, Matthew Lin, Erica Dalla, Jeremiah J. Faith, Manasi Agrawal, Alice O. Kamphorst, Ivan Reyes Torres, Luisanna Pia, Monica Centa, Jessica Tan, Brian D. Brown, Jonathan Chung, Graham J. Britton, Miriam Saffern, Assaf Magen, Matthew P. Spindler, Conor Gruber, Saurabh Mehandru, Amir Horowitz, Timothy O'Donnell, Florian Krammer, Jill Gregory, Gabrielle Lubitz, Pauline Hamon, Meriem Belabed, Matthew Brown, Emma Risson, Louise Malle, Emilie K. Grasset, Alfonso R. Sanchez-Paulete, Justine Noel, Zafar Mahmood, Daniel Lozano-Ojalvo, Mark P. Roberto, Julia Kodysh, Verena van der Heide, Evan Cody, Elliot Meritt, Chang Moon, Maria Suprun, Andrew Leader, Bérengère Salomé, Nicolas F. Fernandez, Dusan Bogunovic, Michelle Tran, Nicolas Vabret, Dirk Homann, Miyo Ota, Cansu Cimen Bozkus, Andrew Charap, Divya Jha, Konstantina Alexandropoulos, Etienne Humblin, Benjamin Greenbaum, Maria Kuksin, Gustavo Martinez-Delgado, Andrew K Chan, Myvizhi Esai Selvan, C. Matthias Wilk, Maria A. Curotto de Lafaille, Samarth Hegde, Alessandra Soares Schanoski, Joel Kim, Jaime Mateus-Tique, Alvaro Moreira, John A. Grout, Rachel Levantovsky, Natalie Vaninov, Peter S. Heeger, Mark Aleynick, Matthew D. Park, Judy H. Cho, Miriam Merad, Steven T. Chen
Publikováno v:
Immunity
The coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an unprecedented effort from the scientific community to understand the biolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ebe77d2897f47bc85766b7d390b28f
http://europepmc.org/articles/PMC7200337
http://europepmc.org/articles/PMC7200337
Autor:
Keino Hutchinson, Brian Brown, Joshua Brody, Judit Svensson-Arvelund, Mark Aleynick, Thomas U. Marron, Linda Hammerich, Netonia Marshall, Miriam Merad, Ranjan Upadhyay
Publikováno v:
Cancer discovery. 9(11)
T-cell transfer into lymphodepleted recipients induces homeostatic activation and potentiates antitumor efficacy. In contrast to canonical T-cell receptor–induced activation, homeostatic activation yields a distinct phenotype and memory state whose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ac918e222cb5317d4f5010280b9f8f5
https://pubmed.ncbi.nlm.nih.gov/31676562
https://pubmed.ncbi.nlm.nih.gov/31676562
Autor:
Mark Aleynick, Paul Peng, Ranjan Upadhyay, Linda Hammerich, Vladimir Roudko, Michael Yellin, Joshua Brody
Publikováno v:
The Journal of Immunology. 202:70.9-70.9
BACKGROUND In situ vaccination (ISV) against lymphoma can be achieved with Flt3-ligand treatment to recruit dendritic cells (DC), radiotherapy to load DC with tumor antigens, and intratumoral injection of a pattern-recognition- receptor agonist (PRRa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e03084064d130352ac62830c23f8361
https://doi.org/10.4049/jimmunol.202.supp.70.9
https://doi.org/10.4049/jimmunol.202.supp.70.9
Autor:
Brian D. Brown, Paul Peng, Netonia Marshall, Thomas A. Davis, Linda Hammerich, Tibor Keler, Judith Agudo, Joshua Brody, Michael Yellin, Mark Aleynick, Ranjan Upadhyay
Publikováno v:
Journal of Clinical Oncology. 36:123-123
123 Background: In patients with low-grade lymphoma, in situ vaccination has yielded both partial and complete remissions in clinical trials. Though clinical responses have been observed with multiple pattern recognition receptor agonists (PRRa), the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ee891466cf0f9a742d02cd817ead845
https://doi.org/10.1200/jco.2018.36.5_suppl.123
https://doi.org/10.1200/jco.2018.36.5_suppl.123
Autor:
Paul Peng, Mark Aleynick, Judith Agudo, Linda Hammerich, Brian D. Brown, Joshua Brody, Antoine Tanne, Nina Bhardwaj
Publikováno v:
Journal of Clinical Oncology. 34:e14516-e14516
e14516Background: In patients with advanced-stage lymphoma, in situ vaccination has yielded partial and complete remissions in phase I/II clinical trials. Though responses have been observed with v...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30019c091105ef53162ccd83ee6d9ee2
https://doi.org/10.1200/jco.2016.34.15_suppl.e14516
https://doi.org/10.1200/jco.2016.34.15_suppl.e14516